Passage BIO (PASG) Preferred Stock Liabilities (2019)
Passage BIO (PASG) posted quarterly Preferred Stock Liabilities of $230.6 million for Q4 2019, up 109.84% quarter-over-quarter from $109.9 million in Q3 2019.
Passage BIO (PASG) Preferred Stock Liabilities (2019) Analysis & Trends
Passage BIO's Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $230.6 million for Q4 2019.
- In Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $230.6 million; the TTM figure through Dec 2019 stood at $230.6 million (changed N/A YoY), while the FY2019 annual figure was $230.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2019 stood at $230.6 million, up from $109.9 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $230.6 million in Q4 2019, with the low at $63.1 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Passage BIO | 15.05 Mn | 15.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 230.61 Mn |
| Sep 30, 2019 | 109.90 Mn |
| Jun 30, 2019 | 74.40 Mn |
| Mar 31, 2019 | 63.10 Mn |